<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=192888919167017&amp;ev=PageView&amp;noscript=1">
Friday, March 29, 2024
March 29, 2024

Linkedin Pinterest

Biotech firm secures $5.1M to further work in proteins

By The Columbian
Published: April 11, 2016, 4:34pm

AbSci, a biotechnology company that will soon relocate from Portland to the former Red Lion Hotel Vancouver at the Quay, has secured $5.1 million in Series A financing to advance its work on producing high yields of soluble, active therapeutic proteins for commercial production of insulin and other therapeutic uses.

A news release describes AbSci as “a global leader in cutting-edge protein production technologies committed to reducing costs in the biopharmaceutical industry.”

The financing is led by Phoenix Venture Partners, a Silicon Valley venture capital firm that invests in companies working to commercialize emerging materials science innovations. AbSci will use the funding to support further development and scale-up of its SoluProTM platform.

“AbSci’s technology enables greater manufacturing flexibility and dramatically more efficient use of existing manufacturing infrastructure,” Zach Jonasson, a co-founder and general partner at Phoenix Venture Partners, said in a news release.

The company, with 13 employees, expects to move to the former Red Lion in mid-June.

Loading...